

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1726358> since 2020-02-03T14:16:39Z

*Published version:*

DOI:10.1016/j.jaci.2019.11.040

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Long-term air pollution exposure is associated with increased severity of rhinitis in two**  
2 **European cohorts**

3 Burte E, PhD<sup>1,2,3,4</sup>, Leynaert B, PhD<sup>5</sup>, Marcon A, PhD<sup>6</sup>, Bousquet J, MD<sup>1,2,7</sup>, Benmerad M, MSc  
4 <sup>8</sup>, Bono R, PhD<sup>9</sup>, Carsin AE, MSc<sup>3,4,10,11</sup>, de Hoogh K, PhD<sup>12,13</sup>, Forsberg B, PhD<sup>14</sup>, Gormand  
5 F, MD<sup>15</sup>, Heinrich J, PhD<sup>16,17</sup>, Just J, MD<sup>18,19</sup>, M Nieuwenhuijsen, PhD<sup>3,4,10,11</sup>, Pin I, MD<sup>8,20</sup>,  
6 Stempfelet M, MSc<sup>21</sup>, Sunyer J, MD, PhD<sup>3,4,10,11</sup>, Villani S, PhD<sup>22</sup>, Künzli N, PhD<sup>12,13</sup>, Siroux  
7 V, PhD<sup>8</sup>, Jarvis D, MD, PhD<sup>23,24</sup>, Nadif R, PhD<sup>1,2\*</sup>, Jacquemin B, MD, PhD<sup>1,2,3,10\*</sup>

8 \* These authors contributed equally to this study

1. INSERM, U1168, VIMA: Aging and chronic diseases. Epidemiological and public health approaches, Villejuif, France
2. Univ Versailles St-Quentin-en-Yvelines, UMR 1168, F-78180, Montigny le Bretonneux, France
3. ISGLocal, Barcelona, Spain.
4. Universitat Pompeu Fabra (UPF), Barcelona, Spain.
5. Inserm, UMR 1152, Pathophysiology and Epidemiology of Respiratory Diseases, Paris, France;
6. Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona;
7. University Hospital, Montpellier, France; MACVIA-France, Contre les MALadies Chroniques pour un Vieillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier;
8. Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Inserm U1209, CNRS, University Grenoble Alpes, Institute for Advanced Biosciences (IAB), Grenoble, France
9. Dept of Public Health and Pediatrics, University of Turin, Turin.
10. CIBER Epidemiología y Salud Pública (CIBERESP), Spain.
11. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
12. Swiss Tropical and Public Health Institute, Basel, Switzerland
13. University of Basel, Basel, Switzerland
14. Dept of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
15. CHU de Lyon, Pneumology Dept, Lyon, France.
16. Ludwig Maximilians University Munich, University Hospital Munich, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Munich, Germany
17. Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research
18. Allergology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Armand-Trousseau
19. Sorbonne Université Paris 6, Paris, France
20. Pédiatrie, CHU de Grenoble Alpes, Grenoble, France.
21. Santé Publique France, 12, rue du Val d'Osne, 94415 Saint-Maurice, France.
22. Unit of Biostatistics and Clinical Epidemiology, Dept of Public Health, Experimental and Forensic Medicine University of Pavia, Pavia.
23. National Heart and Lung Institute, Imperial College London, London, United Kingdom
24. MRC Centre for Environment and Health, School of Public Health, London, United Kingdom

9

10 **Acknowledgment and Funding:**

Funding:

11 ECRHS was supported by the European Commission, as part of their Quality of Life program.

12 The coordination of ECRHS II was supported by the European Commission, as part of their Quality of  
13 Life program.

14 The following bodies funded the local studies in ECRHS II in this article: **Albacete**-Fondo de  
15 Investigaciones Santarias (grant code: 97/0035-01, 13 99/0034-01, and 99/0034-02), Hospital  
16 Universitario de Albacete, Consejería de Sanidad. **Antwerp**-FWO (Fund for Scientific Research)-  
17 Flanders Belgium (grant code: G.0402.00), University of Antwerp, Flemish Health Ministry.  
18 **Barcelona**-Fondo de Investigaciones Sanitarias (grant code: 99/0034- 01, and 99/0034-02), Red Respira  
19 (RTIC 03/11 ISC IIF). Ciber of Epidemiology and Public Health has been established and founded by  
20 Instituto de Salud Carlos III. **Erfurt**-GSF–National Research Centre for Environment & Health,  
21 Deutsche Forschungsgemeinschaft (DFG) (grant code FR 1526/1-1). **Galdakao**-Basque Health  
22 Department. **Grenoble**-Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000  
23 no.2610, Ministry of Health, Direction de la Recherche Clinique, Ministère de l’Emploi et de la  
24 Solidarité, Direction Générale de la Santé, CHU de Grenoble, Comité des Maladies Respiratoires de  
25 l’Isère. **Ipswich and Norwich** National Asthma Campaign (UK). **Huelva**-Fondo de Investigaciones  
26 Sanitarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02). **Oviedo**-Fondo de  
27 Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02). **Paris**-Ministère  
28 de l’Emploi et de la Solidarité, Direction Générale de la Santé, UCBPharma (France), Aventis (France),  
29 Glaxo France, Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no. 2610,  
30 Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble. **Pavia**-Glaxo, Smith & Kline  
31 Italy, Italian Ministry of University and Scientific and Technological Research 3 (MURST), Local  
32 University Funding for Research 1998 & 1999 (Pavia, Italy). **Turin**-ASL 4 Regione Piemonte (Italy),  
33 AO CTO/ICORMA Regione Piemonte (Italy), Ministero dell’Università e della Ricerca Scientifica  
34 (Italy), Glaxo Wellcome spa (Verona, Italy). **Umeå**- Swedish Heart Lung Foundation, Swedish  
35 Foundation for Health Care Sciences & Allergy Research, Swedish Asthma & Allergy Foundation,  
36 Swedish Cancer & Allergy Foundation. **Verona**-University of Verona; Italian Ministry of University  
37 and Scientific and Technological Research (MURST); Glaxo, Smith & Kline Italy.

38

39 EGEA is funded in part by PHRC-Paris, PHRC-Grenoble, ANR 05-SEST-020-02/05-9-97, ANR-06-  
40 CEBS, ANR-CES-2009, Région Nord Pas-de-Calais, Merck Sharp & Dohme (MSD)

41

42 Acknowledgment:

43 ECRHS

44 The ECRHS data incorporated in this analysis would not have been available without the collaboration  
45 of the following individuals and their research teams.

46 **ECRHS Co-ordinating centre:** P Burney, D Jarvis, S Chinn, J Knox (ECRHS II), C Luczynska+ , J  
47 Potts.

48 **Steering Committee for ECRHS II:** P Burney, D Jarvis, S Chinn, J.M Anto, I.Cerveri, R.deMarco ,  
49 T.Gislason, J.Heinrich, C. Janson, N. Kunzli, B. Leynaert, F. Neukirch, T. Rochat, J. Schouten, J.  
50 Sunyer; C. Svanes, P. Vermeire+ , M. Wjst.

51 **Principal Investigators and Senior Scientific Teams for ECRHS II:** Australia: Melbourne (M  
52 Abramson, R Woods, EH Walters, F Thien), Belgium: South Antwerp & Antwerp City (P Vermeire+ ,  
53 J Weyler, M Van Sprundel, V Nelen), Denmark: Aarhus (EJ Jensen), Estonia: Tartu (R Jogi, A Soon),  
54 France: Paris (F Neukirch, B Leynaert, R Liard, M Zureik), Grenoble (I Pin, J Ferran-Quentin),  
55 Bordeaux (A Taytard, C Raheison), Montpellier (J Bousquet, P Demoly)Germany: Erfurt (J Heinrich,  
56 M Wjst, C Frye, I Meyer) Hamburg (K Richter),Iceland: Reykjavik (T Gislason, E Bjornsson, D  
57 Gislason, T Blondal, A Karlsdottir), Italy: Turin (M Bugiani, R Bono, P Piccioni, E Caria, A Carosso,  
58 E Migliore, G Castiglioni), Verona (R de 5 Marco, G Verlato, E Zanolin, S Accordini, A Poli, V Lo  
59 Cascio, M Ferrari), Pavia (A Marinoni, S Villani, M Ponzio, F Frigerio, M Comelli, M Grassi, I Cerveri,  
60 A Corsico),Netherlands: Groningen & Geleen (J Schouten, M Kerkhof), Norway: Bergen (A Gulsvik,  
61 E Omenaas, C Svanes, B Laerum), Spain: Barcelona (JM Anto, J Sunyer, M Kogevinas, JP Zock, X  
62 Basagana, A Jaen, F Burgos), Huelva (J Maldonado, A Pereira, JL Sanchez), Albacete (J  
63 MartinezMoratalla Rovira, E Almar), Galdakao (N Muniozguren, I Urritia), Oviedo (F Payo), Sweden:  
64 Uppsala (C Janson, G Boman, D Norback, M Gunnbjornsdottir), Goteborg (K Toren, L Lillienberg, AC  
65 Olin, B Balder, A Pfeifer-Nilsson, R Sundberg), Umea (E Norrman, M Soderberg, K Franklin, B  
66 Lundback, B Forsberg, L Nystrom),Switzerland: Basel (N Kunzli, B Dibbert, M Hazenkamp, M  
67 Brutsche, U Ackermann-Liebrich); UK: Norwich (D Jarvis, B Harrison), Ipswich (D Jarvis, R Hall, D  
68 Seaton), USA: Portland (M Osborne, S Buist, W Vollmer, L Johnson)

69 EGEA:

70 **Coordination:** V Siroux (epidemiology, PI since 2013); F Demenais (genetics); I Pin (clinical aspects);  
71 R Nadif (biology); F Kauffmann (PI 1992-2012). **Respiratory epidemiology:** Inserm ex-U 700, Paris:  
72 M Korobaeff (Egea1), F Neukirch (Egea1); Inserm ex-U 707, Paris: I Annesi-Maesano (Egea1-2);  
73 Inserm ex-U 1018, Villejuif: F Kauffmann, MP Oryszczyn (Egea1-2); Inserm U 1168, Villejuif: N Le  
74 Moual, R Nadif, R Varraso; Inserm U 1209 Grenoble: V Siroux. **Genetics:** Inserm ex-U 393, Paris: J  
75 Feingold; Inserm U 946, Paris: E Bouzigon, F Demenais, MH Dizier; CNG, Evry: I Gut (now CNAG,

76 Barcelona, Spain), M Lathrop (now Univ McGill, Montreal, Canada). **Clinical centers:** Grenoble: I Pin,  
77 C Pison; Lyon: D Ecochard (Egea1), F Gormand, Y Pacheco; Marseille: D Charpin (Egea1), D Vervloet  
78 (Egea1-2); Montpellier: J Bousquet; Paris Cochin: A Lockhart (Egea1), R Matran (now in Lille); Paris  
79 Necker: E Paty (Egea1-2), P Scheinmann (Egea1-2); Paris-Trousseau: A Grimfeld (Egea1-2), J Just.  
80 **Data and quality management:** Inserm ex-U155 (Egea1): J Hochez; Inserm U 1168, Villejuif: N Le  
81 Moual; Inserm ex-U780: C Ravault (Egea1-2); Inserm ex-U794: N Chateigner (Egea1-2); Grenoble: J  
82 Quentin (Egea1-2).

83 **Conflict of interest:**

84 Pr. JUST reports personal fees and grants from Novartis and Astrazeneca, personal fees from GSK,  
85 Sanofi and ALK , outside the submitted work.

86 Pr Bousquet is a member of POLLAR (Impact of air POLLution on Asthma and Rhinitis, EIT  
87 Health).

88 The other authors have no conflict of interest to disclose related to this work.

89 **Corresponding author:**

90 Bénédicte Jacquemin,

91 INSERM, U1168, VIMA: Aging and chronic diseases, Epidemiological and Public health  
92 approaches, F-94807, Villejuif, France. Phone number: 33 (0) 145 59 50 22, Fax number: 33  
93 (0) 145 59 51 69

94 E-mail: [benedicte.jacquemin@inserm.fr](mailto:benedicte.jacquemin@inserm.fr)

95

96

97 **Abstract:**

98 **Background:** Very few studies have examined the association between long-term outdoor air  
99 pollution and rhinitis severity in adults.

100 **Objective:** To assess the cross-sectional association between individual long-term exposure to  
101 air pollution and severity of rhinitis.

102 **Methods:** Participants with rhinitis from two multicentre European cohorts (EGEA and  
103 ECRHS) were included. Annual exposure to NO<sub>2</sub>, PM<sub>10</sub>, PM<sub>2.5</sub> and PM<sub>coarse</sub> (calculated by  
104 subtracting PM<sub>2.5</sub> from PM<sub>10</sub>) was estimated using land-use regression models derived from the  
105 ESCAPE project, at the participants' residential address. The score of rhinitis severity (range  
106 0-12), based on intensity of disturbance due to symptoms reported by questionnaire, was  
107 categorized in low (reference), mild, moderate and high severity. Polytomous logistic  
108 regression models with a random intercept for city were used.

109 **Results:** 1408 adults with rhinitis (mean age: 52 years, 46% men, 81% from ECRHS) were  
110 included. The median [Q1-Q3] score of rhinitis severity was 4 [2-6]. Higher exposure to PM<sub>10</sub>  
111 was associated with higher rhinitis severity (aOR[95% CI] for a 10 µg/m<sup>3</sup> increase of PM<sub>10</sub>: for  
112 mild: 1.20[0.88-1.64], moderate: 1.53[1.07-2.19], and high severity: 1.72[1.23-2.41]). Similar  
113 results were found for PM<sub>2.5</sub>. Higher exposure to NO<sub>2</sub> was associated with an increased severity  
114 of rhinitis, with similar aORs whatever the level of severity. aORs were higher among  
115 participants without allergic sensitization than in those with, but interaction was found only for  
116 NO<sub>2</sub>.

117 **Conclusions:** People with rhinitis who live in areas with higher levels of pollution are more  
118 likely to report more severe nasal symptoms – further work is required to elucidate the  
119 mechanisms of this association.

120

121 **Total word count:** 251

122

123 **Capsule summary:** People with rhinitis who live in areas with higher levels of pollution are  
124 more likely to report more severe nasal symptoms – further work is required to elucidate the  
125 mechanisms of this association.

126

127

128 **Key messages:**

- 129 • Very little is known about air pollution as risk factor for rhinitis and its phenotypes in  
130 adults
- 131 • Air pollution and particularly particulate matter is associated with an increase in rhinitis  
132 severity
- 133 • Air pollution needs to be controlled

134

135 **Keywords:** rhinitis, allergic sensitization, air pollution, environment, severity, respiratory  
136 disease

137

138

139 **Abbreviations:**

140 ARIA: Allergic Rhinitis and its Impact on Asthma

141 ECRHS: European Community Respiratory Health Survey

142 EGEA: Epidemiological Study on the Genetics and Environment on Asthma

143 ESCAPE: European Study of Cohorts for Air Pollution Effects

144 LUR: Land-Use Regression

145 NO<sub>2</sub>: nitrogen dioxide

146 OR: Odds Ratio

147 PM: Particulate matter

148 SAR: Seasonal Allergic Rhinitis

149

150 Introduction

151 Rhinitis is a very frequent disease affecting between 20% and 50% of the population according  
152 to countries and definitions (Bousquet et al. 2008; Katelaris et al. 2012; Wang et al. 2014). The  
153 principal symptoms of rhinitis are sneezing and runny, blocked or itchy nose, in absence of a  
154 cold or the flu (Bousquet and Cauwenberge 2002). Often considered as a trivial disease, rhinitis  
155 does actually have an important impact on quality of life (Bousquet et al. 2013; Leynaert et al.  
156 2000). Rhinitis is generally divided into allergic and non-allergic rhinitis, often differing in  
157 terms of symptoms, duration, treatment, seasonality and/or severity (Papadopoulos et al. 2015;  
158 Quillen and Feller 2006). Very little is known about the environmental risk factors of rhinitis  
159 and its different phenotypes, including air pollution (Heinrich 2018). As rhinitis is frequently  
160 associated with asthma (Shaaban et al. 2008) for which air pollution has been shown to strongly  
161 aggravate symptoms (Rage et al. 2009), and even induce the disease (Guarnieri and Balmes  
162 2014), it is a genuine question to wonder about the effects of air pollution on rhinitis.

163 There are very few studies focusing on the association between air pollution and rhinitis in  
164 adults. Short-term exposure to air pollution has been associated with exacerbation of rhinitis  
165 leading to more daily clinical examinations (Hajat et al. 2001; Zhang et al. 2011). However,  
166 association between long-term air pollution and rhinitis severity has scarcely been studied. One  
167 large French study assessing the link between grass pollen counts, air pollution levels and  
168 severity of seasonal allergic rhinitis found a positive but not statistically significant association  
169 between air pollutant level and severe allergic rhinitis (Annesi-Maesano et al. 2012). However,  
170 this study only considered seasonal allergic rhinitis and no other phenotypes. Recently, an  
171 American study examined the relationship between PM<sub>2.5</sub> (airborne particles with an  
172 aerodynamic diameter  $\leq 2.5 \mu\text{m}$ ) and black carbon and rhinitis in 125 patients with chronic  
173 rhinosinusitis with and without polyps (Mady et al. 2018). They found significantly higher  
174 exposure levels of PM<sub>2.5</sub> and black carbon among participants without allergic sensitization  
175 compared to those with allergic sensitization, and also found an association between black  
176 carbon and non-allergic symptoms of rhinitis. In a previous study, we found no consistent  
177 evidence for an association between long-term exposure to air pollution and incidence of  
178 rhinitis, whether allergic or non-allergic (Burte et al. 2018). We hypothesized that air pollution  
179 may not induce rhinitis development, but may still be associated with an increase in severity of  
180 the disease.



181 In the present study, we aimed to examine the association between long term exposure to air  
182 pollution and severity of allergic and non-allergic rhinitis in two European studies.

183

184 Methods:

### 185 **Study design and settings**

186 Participants included in the analysis were those suffering from rhinitis at the second follow-up  
187 (2011-2013) of two large multicentre epidemiological European studies: the European  
188 Community Respiratory Health Survey (ECRHS) and the Epidemiological Study on the  
189 Genetics and Environment on Asthma (EGEA).

190 The EGEA ((Kauffmann 1999; Kauffmann et al. 1997), <https://egeanet.vjf.inserm.fr/>) is a  
191 French cohort of 2,047 participants (asthma patients –adults or children- enrolled from hospital  
192 chest clinics, their first-degree relatives, and controls who were recruited from other hospital  
193 wards or from electoral lists) enrolled between 1991 and 1995 from five French cities. A first  
194 follow-up was conducted between 2003 and 2007 (EGEA2, N=2121, (Kauffmann et al. 1997;  
195 Siroux et al. 2009)) and a second between 2011 and 2013 (EGEA 3, N=1558, (Bouzigon et al.  
196 2015)).

197 The ECRHS (Burney et al. 1994) is a population-based cohort of young adults, enriched with  
198 participants with respiratory symptoms, recruited from 1992 to 1994 in 28 western European  
199 cities (ECRHS I, N=17880, <http://www.ecrhs.org/>) and followed up twice: between 2000 and  
200 2002 (ECRHS II, n=10933, European Community Respiratory Health Survey II Steering  
201 Committee 2002) and between 2011 and 2013 (ECRHS III, N=7040).

202 Participants of both studies were extensively characterized with regard to their respiratory  
203 health and risk factors using similar standardized protocols and questionnaires. Ethical approval  
204 was obtained in each study from the appropriate institutional ethics committees and written  
205 informed consent was obtained from each participant.

206

### 207 **Definition of rhinitis**

208 In this cross-sectional analysis, report of ever rhinitis was defined by a positive response to  
209 “*Have you ever had a problem with sneezing, or a runny or a blocked nose when you did not*  
210 *have a cold or the flu?*” in EGEA3 and ECRHS III.

211 Among those who had reported ever rhinitis, rhinitis in the last 12 months was defined by a  
212 positive response to “*Have you ever had a problem with sneezing, or a runny or a blocked nose*  
213 *when you did not have a cold or the flu in the last 12 months?*” in EGEA3 and ECRHS III.

214

### 215 **Definition of score of severity of rhinitis (based on symptoms of rhinitis)**

216 A numeric score of severity of rhinitis was assessed at EGEA3 and ECRHSIII, adapted from  
217 the Symptomatic Global Score for seasonal allergic rhinitis (Rouve et al. 2010). This score was  
218 calculated on the basis of the answers to question on severity of the four main symptoms of  
219 rhinitis (watery runny nose, blocked nose, itchy nose and sneezing). In case of missing data for  
220 severity of one or more symptoms, no imputation was done and these participants were not  
221 included in the analyses. For each of the four items, participants had to indicate how important  
222 the symptom had hampered their daily life in the last 12 months:

223 0. No problem (symptom not present)

224 1. A problem that is/was present but not disturbing

225 2. A disturbing problem but not hampering day time activities or sleep

226 3. A problem that hampers certain activities or sleep

227 Each question scored from 0 to 3 and thus summing the answers to these 4 questions, the overall  
228 score ranged from 0 to 12, the higher score indicating a higher severity. The overall score was  
229 further categorized into four levels according to the quartiles of the distribution: low severity  
230 (score  $\leq 2$ ), mild severity (score = 3 or 4), moderate severity (score = 5 or 6) and high severity  
231 (score  $\geq 7$ ). Low severity was considered as the reference in the analyses.

232 Additionally, severity was analysed symptom by symptom, using the following classification  
233 to approximate closely the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (2):  
234 The category 0 was considered as the reference compared to mild rhinitis (1), and  
235 moderate/severe rhinitis (2/3 pooled together).

236

### 237 **Definition of allergic sensitization**

238 In EGEA2, allergic sensitization was defined using skin-prick test (SPT) for 12 aeroallergens  
239 (mean wheal diameter 3mm  $\geq$  than the negative control to at least one of the following allergens:

240 cat, *Dermatophagoides pteronyssinus*, *Blattella germanica*, olive, birch, *Parietaria judaica*,  
241 timothy grass, ragweed pollen, *Aspergillus*, *Cladosporium herbarum*, *Alternaria tenuis*).

242 In ECRHS II, allergic sensitization was defined using specific Immunoglobulin E (IgE) to four  
243 allergens (specific IgE $\geq$ 35kU/mL to at least one of the following allergens:  
244 cat, *Dermatophagoides pteronyssinus*, *Cladosporium*, and timothy grass).

245

## 246 **Definition of asthma**

247 Ever asthma was defined by a positive response to “*Have you ever had asthma?*” in ECRHS  
248 III; and by a positive response to one of the following questions “*Have you ever had attacks of*  
249 *breathlessness at rest with wheezing?*” or “*Have you ever had asthma attacks?*” at EGEA1,  
250 EGEA2 or EGEA3 or by being recruited as asthmatic cases in EGEA 1 (Siroux et al. 2011).

251

## 252 **Estimation of air Pollution exposure**

253 Long-term exposure to pollutants was estimated using land use regression models derived from  
254 the European Study of Cohorts for Air Pollution Effects (ESCAPE [www.escapeproject.eu](http://www.escapeproject.eu)  
255 (Beelen et al. 2013; Eeftens et al. 2012)) project. The home addresses of the participants at  
256 EGEA2 and ECRHS II, living in ESCAPE cities were geocoded. As no exposure data at the  
257 same year of EGEA2 or ECRHS II was available, the exposure at the closest year was used.  
258 Therefore, geocodes were linked with ambient concentrations of air pollutants estimated using  
259 land-use regression (LUR) models between 2009 and 2010. Available air pollutants were: NO<sub>2</sub>  
260 (nitrogen dioxide), PM<sub>10</sub> (airborne particles with an aerodynamic diameter  $\leq$ 10  $\mu$ m), PM<sub>2.5</sub> and  
261 PM<sub>coarse</sub> (airborne particles with an aerodynamic diameter ranging from 2.5 to 10 $\mu$ m,  
262 calculated by subtracting PM<sub>2.5</sub> from PM<sub>10</sub>). Estimates of NO<sub>2</sub> were available for all 17 cities  
263 (Umea, Norwich, Ipswich, Antwerp, Erfurt, Paris, Lyon, Grenoble, Marseille, Verona, Pavia,  
264 Turin, Oviedo, Galdakao, Barcelona, Albacete and Huelva) and estimates of all PM metrics for  
265 6 cities (Norwich, Ipswich, Antwerp, Paris, Grenoble, Turin and Barcelona). Data on two traffic  
266 exposure indicators -traffic intensity (on the nearest road), and traffic load (in a 100m buffer)-  
267 were also available.

268

## 269 **Statistical analysis**

270 Associations between long-term exposure to air pollutants (estimated at participants' residential  
271 addresses at the first follow-up of each study, thus between 2000 and 2007) and the severity  
272 score of rhinitis (assessed at the second follow-up of each study, thus between 2011 and 2013)  
273 were analysed using polytomous logistic regression. To account for between-city heterogeneity,  
274 a random intercept for city was used (GLLAMM procedure in STATA14).

275 Models were carried out without any adjustment, and then adjusted on pre-selected variables  
276 based on previous literature: age, sex, smoking status, asthma and allergic sensitization.  
277 Analyses with traffic density or traffic load were further adjusted for NO<sub>2</sub> background level as  
278 described in the ESCAPE protocol. Results are presented as odds ratio (OR) with the associated  
279 95% confidence interval associated. Estimates were reported for an increase of 10 µg/m<sup>3</sup> for  
280 NO<sub>2</sub> and PM<sub>10</sub>, 5 µg/m<sup>3</sup> for PM<sub>2.5</sub> and PM<sub>coarse</sub>, 4,000,000 vehicles\*m/day for traffic load on  
281 all major roads in a 100m buffer and 5,000 vehicles/day for traffic density on the nearest road,  
282 following ESCAPE protocol.

283 Considering that air pollution may act differently according to allergic sensitization, a stratified  
284 analysis on allergic sensitization status was carried out. As air pollution is known to increase  
285 asthma severity and as asthma and rhinitis are strongly related, a stratified analysis on asthma  
286 status was also carried out. Smokers have a continual bombardment of the nasal cavities with  
287 PM and irritant gases from cigarette smoke, which could affect pollutant response and thus a  
288 stratified analysis on smoking status (current smokers vs. ex or never smokers) was carried out.  
289 Finally, since the design of ECRHS and EGEEA differed, a stratified analysis on study was also  
290 carried out on the study. The interactions between each pollutant and each factor of stratification  
291 were tested by likelihood ratio tests in separate models.

292 To test if association between air pollution and severity of rhinitis differs according to the type  
293 of symptom, the association between air pollutants and severity of each of the four symptoms  
294 separately was estimated.

295 Sensitivity analyses were performed: as treatment may have lowered severity, analysis  
296 excluding participants with medication in the last 12 months (use of medication –pills or spray-  
297 to treat nasal disorder in the last 12 months) was performed. Given that the methods used to  
298 take into account the within-city (or centre) correlation is a complex issue (Basagaña et al.  
299 2018), and to ensure robustness of our results, simple polytomous regressions without adding a  
300 city level intercept were also performed. As participants may have moved between the first and  
301 the second follow-up of both studies, we also performed the fully adjusted analysis among non-

302 movers only to ensure robustness of the results. Since only half of the population has PM data  
303 and to ensure comparability of the results, analyses with NO<sub>2</sub> were also performed in the  
304 restricted population with PM exposure data.

305 Bi-pollutant models including NO<sub>2</sub> and each one of the PM metrics were also performed to test  
306 the independence of the results for each of the pollutant.

307 All analyses were carried out by Stata (Stata 14)).

308

### 309 Results:

310 This study included 1408 participants from EGEA3 and ECRHS III with symptoms of rhinitis  
311 in the last 12 months, having available data on rhinitis severity score and individual air pollution  
312 estimates (Flow-chart available in Figure 1).

313 A detailed description of the characteristics of the 1408 participants is reported in Table 1, for  
314 all participants and according to the four levels of severity of rhinitis. ECRHS contributed with  
315 81% of the study population. Participants were on average 52.3 years old, 54.4% were women  
316 and 28% had asthma. The median severity score of rhinitis was 4 ([Q1-Q3]=[2-6]). When  
317 increasing in the severity category, participants were younger, more often from the EGEA  
318 study, and more often had asthma and allergic sensitization (from 18% in low severity to 39%  
319 in high severity and from 35% in low severity to 64% in high severity respectively). Participants  
320 with higher severity also reported allergic rhinitis or hay fever more often (from 34% for low  
321 severity to 81% for high severity) as well as more frequent symptoms of rhinitis.

322 An increase in air pollution exposure was associated with an increased in the severity of rhinitis  
323 (Figure 2, exact ORs in Table S2 in Supplementary material). Increased levels of PM<sub>10</sub> and  
324 PM<sub>2.5</sub> were associated with higher levels of severity, with an exposure-response association. A  
325 similar pattern was found for PM<sub>coarse</sub> with a slightly lower effect and reaching statistical  
326 significance only for high severity. For NO<sub>2</sub>, there was no exposure-response relationship. ORs  
327 for mild, moderate and high severity were similarly estimated at around 1.15. No association  
328 was found between traffic load or traffic intensity and score of severity.

329

### 330 *Stratified analyses*

#### 331 Stratification by allergic sensitization

332 Among participants with no allergic sensitization, increase in NO<sub>2</sub>, PM metrics and traffic  
333 intensity exposure were associated with an increased severity score of rhinitis, with an  
334 exposure-response relationship (Figure 3 and Table S2 in Supplementary material). Among  
335 participants with allergic sensitization, increase in air pollution exposure was associated with  
336 an increased severity score of rhinitis only for PM<sub>2.5</sub>. No association was found for the other  
337 pollutants. A statistically significant interaction was found between allergic sensitization and  
338 NO<sub>2</sub> (p-interaction of the likelihood-ratio test= 0.02), at borderline statistical significance for  
339 traffic load (p-interaction=0.05) and traffic intensity (p-interaction=0.08), and not statistically  
340 significant for PM<sub>10</sub> (p-interaction=0.26), PM<sub>2.5</sub> (p-interaction=0.21) and PM<sub>coarse</sub> (p-  
341 interaction=0.24).

342

#### 343 Stratification by asthma status

344 Among the participants without asthma, an increase in air pollution exposure was associated  
345 with an increased severity score of rhinitis -similar to the results of the participants without  
346 allergic sensitization-(Table S2 in Supplementary material). In contrast, in the participants with  
347 asthma, an increase in air pollution exposure was not associated with an increased severity score  
348 of rhinitis – similar to the results of the participants with allergic sensitization. An interaction  
349 was found for NO<sub>2</sub> (p-interaction =0.007) and for traffic load (p-interaction=0.03) and no  
350 interaction was found between other pollutants and asthma (p-interactions>0.11).

#### 351 Stratification by smoking status

352 Among non-smokers, a higher air pollution exposure was associated with an increased severity  
353 score of rhinitis (Table S3 in Supplementary material). In contrast, higher exposure was not  
354 associated with an increased severity score in smokers although all interaction tests were below  
355 conventional levels of significance (p-interactions <0.14)

#### 356 Stratification by study

357 Among participants from the ECRHS study, higher air pollution exposure was associated with  
358 an increased severity score of rhinitis (Table S3 in Supplementary material). In contrast, a  
359 higher exposure was not associated with an increased severity score in participants from the  
360 EGEA study although all interaction tests were below conventional levels of significance (p-  
361 interactions <0.40).

362

363 *Analyses of the association between air pollutants exposure and severity of each symptom of*  
364 *rhinitis*

365 The associations between air pollutants exposure and the symptoms composing the score are  
366 shown in Table S1 of the Supplementary material. In summary, PM<sub>10</sub> and PM<sub>2.5</sub> exposure  
367 increased the severity of blocked nose, itchy nose and sneezing, with an exposure-response  
368 relationship. NO<sub>2</sub> exposure increased the severity of runny and blocked nose when compared  
369 to no symptoms, with a similar effect size for moderate/severe or mild symptoms. No  
370 association was found between NO<sub>2</sub> exposure and severity of itchy nose and sneezing. No  
371 association was found between PM<sub>coarse</sub> exposure and severity of any of the four symptoms.  
372 No association was found between traffic load or traffic intensity and severity of any of the four  
373 symptoms.

374

375 *Sensitivity analyses*

376 When considering only the participants who did not take medicine for rhinitis in the last 12  
377 months, results were similar to those from the main analysis, with a dose-relationship for PM  
378 (Table S4 in Supplementary material). Analyses among non-movers only showed similar  
379 results to those from the main analysis, with even higher ORs for NO<sub>2</sub> and PM metrics (Table  
380 S5 in Supplementary material).

381 In the bi-pollutants models (Table S6 in Supplementary Material), results remained consistent  
382 for PM metrics, with higher OR but wider confidence intervals, leading to only two statistically  
383 significant ORs: for high level of severity for PM<sub>10</sub> and PM<sub>2.5</sub> (Pearson correlation between  
384 NO<sub>2</sub> and PM<sub>2.5</sub>=0.60, between NO<sub>2</sub> and PM<sub>10</sub>=0.70, and NO<sub>2</sub> and PM<sub>coarse</sub>=0.72).  
385 Interestingly, estimates for NO<sub>2</sub> in the bi-pollutant models with PM<sub>10</sub> and PM<sub>coarse</sub> were higher  
386 than those in the main model and were reaching statistical significance for almost all level of  
387 severity.

388 Unadjusted models or models without taking city level into account gave very similar results  
389 as those using adjusted model with a random intercept for city, without changing the statistical  
390 significance of the results (results not shown).

391 Analyses with NO<sub>2</sub> in the restricted population having PM exposure data gave similar results  
392 (results not shown).

393 Discussion

394 In 1,408 participants from two European studies with detailed characterization of rhinitis, we  
395 investigated the association between individual air pollution exposure and severity of rhinitis.  
396 An increase in PM<sub>10</sub> and PM<sub>2.5</sub> exposure was associated with an increased severity of rhinitis.  
397 To a lesser extent, PM<sub>coarse</sub> and NO<sub>2</sub> were also associated with severity of rhinitis, with no  
398 exposure-response relationship for NO<sub>2</sub>. No association was found between traffic load or  
399 traffic intensity and severity of rhinitis.

400 Our study is one of the first to examine the long-term effects of air pollution on the severity of  
401 rhinitis, considering separately allergic and non-allergic rhinitis separately. Previously, a  
402 French study among 17,567 children and adults has modelled the risk of suffering from severe  
403 seasonal allergic rhinitis (SAR) as a function of both grass pollen count and outdoor air  
404 pollution evaluated by daily mean exposure over a period of a few months (Annesi-Maesano et  
405 al. 2012). They found a positive but not statistically significant association between NO<sub>2</sub> or  
406 PM<sub>10</sub> exposure and SAR high severity, with a trend for PM<sub>10</sub>, and with adjustment for pollen  
407 count. Findings from this study cannot be directly compared with our study given the  
408 differences in the phenotype studied, in the definition of severity as they considered high versus  
409 no, low or moderate severity, in the estimation of exposure to air pollution, and given the lack  
410 of results without adjustment on grass pollen. Nevertheless, our results for PM<sub>10</sub> and PM<sub>2.5</sub>  
411 among participants with allergic sensitization seem to be in line with this previous study.  
412 Unfortunately, we did not have data on grass pollen to take into account their interrelation with  
413 air pollutants in the study of allergic rhinitis.

414 One of the weaknesses of our study is the time discrepancy between ESCAPE measurement  
415 and the follow-up dates of the two studies: individual addresses were collected between 2000  
416 and 2007, air pollution was measured and modelled between 2009 and 2010 and severity of  
417 rhinitis was collected between 2011 and 2013. Although the temporality -exposure assessment  
418 before severity assessment- is respected, we did not have the annual exposure corresponding to  
419 the year before questionnaire completion. This is a common problem when dealing with  
420 estimation of long-term annual air pollution. We assume that spatial variability of that specific  
421 year also represents the spatial patterns during previous years (de Hoogh et al. 2016). Our  
422 results among non-movers were similar to those from the main analysis, with even higher ORs,  
423 strengthening the robustness of our results.

424 One of the strength of the present analysis is the appraisal of allergic and non-allergic rhinitis  
425 phenotypes, of rhinitis severity as well as the consideration of different types of symptoms. We



426 found differences in the association between air pollution exposure and severity of rhinitis  
427 according to the phenotype studied. After stratification by allergic sensitization, the effect of  
428 pollutants seemed higher among participants without allergic sensitization than in those with,  
429 although that interaction was statistically significant only for NO<sub>2</sub>. The interactions between  
430 PM metrics and allergic sensitization were not statistically significant. However, we may not  
431 have enough power to find an interaction, as the sample size is almost half for PM analyses  
432 compared to NO<sub>2</sub> analyses. The higher association among participants without allergic  
433 sensitization could be partly supported by the fact that allergic sensitization is already a risk  
434 factor for high severity: there are twice as many participants with allergic sensitization with a  
435 high severity of rhinitis compared to low severity. The effect of pollutants may have a lower  
436 impact on those with already severe rhinitis. However, as discussed before, no association was  
437 found in the study by Annesi-Maesano et al. (Annesi-Maesano et al. 2012) between air pollution  
438 levels and score of allergic rhinitis. In the study by Mady et al., a positive correlation was found  
439 between exposure to black carbon and some symptoms of rhinitis, regardless of allergic  
440 sensitization status, and no results were available for PM<sub>2.5</sub>. Furthermore, this study was based  
441 on a small selected sample of patients with disease, without formal statistical analyses. We had  
442 no data on the seasonality of the symptoms, and thus we were not able to assess whether air  
443 pollution exposure had a different impact on severity of rhinitis, depending on seasonal or “all-  
444 over-the-year” symptoms. We had data on the long-term annual exposure of air pollution and  
445 this study was not designed to investigate short-term/ seasonal variation in nasal symptoms  
446 according to air pollutant levels.

447 Accounting for asthma when assessing the association between air-pollution and rhinitis is not  
448 trivial as rhinitis and asthma are strongly related, and air pollution is known to increase asthma  
449 severity and incidence. Our results were similar when adjusting or not adjusting for asthma.  
450 Stratified analyses on asthma showed a higher effect of air pollutant among participants without  
451 asthma, but the interaction was statistically significant only for NO<sub>2</sub>, as for allergic  
452 sensitization. The similarity of results according to allergic sensitization and according to  
453 asthma is probably due to the fact that allergic sensitization is strongly interrelated to asthma.  
454 Anyway, the association between air pollution exposure and rhinitis severity is most likely not  
455 confused by asthma status.

456 We found that a higher exposure to air pollution was associated with an increased severity of  
457 rhinitis among non-smokers but not among smokers. However, the estimates were of  
458 comparable magnitude or even higher in smokers than in non-smokers, and no interaction was

459 found. These results are probably due to the fact that less than 20% of individuals were current  
460 smokers and therefore the sample size was probably small for such an evaluation. Similarly, we  
461 found that a higher exposure in air pollution was associated with an increased severity in  
462 ECRHS but not in EGEA, which represent around 20% of the individuals of our study.  
463 However, as EGEA is originally a case-control on asthma and thus have a high proportion of  
464 participants with asthma, results from the stratified analyses by study are in line with those from  
465 the analyses stratified by asthma.

466 We found similar results whether or not taking into account the city or including a random  
467 intercept for the city level, suggesting that adding the city level did not provide more  
468 information for the model and thus that the association between air pollution and severity of  
469 rhinitis does not change according to the city. Generally, our results were quite robust as  
470 estimates were similar in crude and adjusted analysis, whether taking the city into account or  
471 not.

472 The ARIA classification on severity was initially built for allergic rhinitis, but it may be  
473 extended to other phenotypes of rhinitis such as non-allergic rhinitis. Indeed, questions used to  
474 define severity are not specifically related to the allergic facet of the disease. Rhinitis is usually  
475 not defined by only one symptom, but by a combination of several symptoms characterizing  
476 the disease as a whole (Bousquet et al. 2008). We have therefore considered the score of severity  
477 in order to appraise the general effect of long-term air pollution on rhinitis severity. However,  
478 some symptoms may be more frequent in allergic rhinitis or non-allergic (Quillen and Feller  
479 2006), and the effect of air pollutant on rhinitis severity may depend of the type of symptom of  
480 rhinitis. In our study, results differed according to the symptom and even if results were slightly  
481 stronger for “blocked nose”, no clear allergic or non-allergic pattern stood out.

482 Our results also differed according to the pollutant studied. Association between PM metrics  
483 and rhinitis severity increased gradually with levels of severity, whereas in the association  
484 between NO<sub>2</sub> exposure, effect size was the same whatever the levels. Both NO<sub>2</sub> and PM metrics  
485 are pollutants related to traffic, but their size and mechanisms of action are different, as well as  
486 how they can interact with pollen (D’Amato et al. 2016, 2018; Diaz-Sanchez 2000). The  
487 interaction between allergic sensitization and asthma status and NO<sub>2</sub> also supports this  
488 hypothesis. The potential mechanisms of action suggested to explain the effects of air pollutants  
489 are related to oxidative stress (Bates et al. 2019), reactive oxygen species, apoptosis and  
490 inflammation (Jang et al. 2016). In our case, gaseous or particulate pollutants seem to both have

491 a distinct effect on rhinitis severity, and this was confirmed by our bi-pollutant model. It is  
492 somehow surprising that associations were weaker or null for PM<sub>coarse</sub>, given that this PM  
493 fraction would be expected to have a higher nasal fractional deposition than PM<sub>2.5</sub>. Particulates  
494 of different aerodynamic diameters may lead to different inflammatory responses in the  
495 respiratory tract (Huang et al. 2017) and the mechanisms underlying the interaction between  
496 PM and the immune system still need to be elucidated and addressed clinically (Wu et al. 2018).  
497 Furthermore, the biological effects of particulates are based on their chemical compositions,  
498 which may depend on the diameter of particulates. We found no clear association between  
499 traffic metrics and severity of rhinitis, a result consistent with previous ESCAPE papers  
500 reporting associations between specific pollutants with asthma and lung function, but not with  
501 traffic metrics (Adam et al. 2015; Jacquemin et al. 2015). All these results bring up the  
502 hypothesis that biological mechanisms by which air pollution may affect rhinitis are not the  
503 same depending on the pollutant as well as on the phenotype of rhinitis studied, and in particular  
504 according to allergic sensitization. Further studies filling the gap between air pollution  
505 exposure, biological markers of inflammation and phenotype of rhinitis are needed to better  
506 understand the underlying mechanisms of the general association.

507 In conclusion, using data from the 1,408 adults with rhinitis from two European studies on  
508 respiratory health, the present study showed that annual air pollution exposure was associated  
509 with increased severity of rhinitis, in particular for PM metrics. These results bring new insights  
510 into the management of rhinitis, a hidden major public health challenge, associated with  
511 substantial daily impairment and high cost to society. Finally, our results contribute to a better  
512 understanding of the environmental risk factors of this disease and re-emphasize the evidence  
513 that air pollution needs to be better controlled.

514

515 References:

- 516 Adam M, Schikowski T, Carsin a. E, Cai Y, Jacquemin B, Sanchez M, et al. 2015. Adult lung function  
517 and long-term air pollution exposure. ESCAPE: a multicentre cohort study and meta-analysis. *Eur.*  
518 *Respir. J.* 45:38–50; doi:10.1183/09031936.00130014.
- 519 Annesi-Maesano I, Rouve S, Desqueyroux H, Jankovski R, Klossek J-M, Thibaudon M, et al. 2012.  
520 Grass pollen counts, air pollution levels and allergic rhinitis severity. *Int. Arch. Allergy Immunol.*  
521 158:397–404; doi:10.1159/000332964.
- 522 Basagaña X, Pedersen M, Barrera-Gómez J, Gehring U, Giorgis-Allemand L, Hoek G, et al. 2018.  
523 Analysis of multicentre epidemiological studies: contrasting fixed or random effects modelling  
524 and meta-analysis. *Int. J. Epidemiol.* 47:1343–1354; doi:10.1093/ije/dyy117.
- 525 Bates JT, Fang T, Verma V, Zeng L, Weber RJ, Tolbert PE, et al. 2019. Review of Acellular Assays of  
526 Ambient Particulate Matter Oxidative Potential: Methods and Relationships with Composition,  
527 Sources, and Health Effects. *Environ. Sci. Technol.* 53:4003–4019; doi:10.1021/acs.est.8b03430.
- 528 Beelen R, Hoek G, Vienneau D, Eeftens M, Dimakopoulou K, Pedeli X, et al. 2013. Development of  
529 NO<sub>2</sub> and NO<sub>x</sub> land use regression models for estimating air pollution exposure in 36 study areas  
530 in Europe - The ESCAPE project. *Atmos. Environ.* 72:10–23;  
531 doi:10.1016/j.atmosenv.2013.02.037.
- 532 Bousquet J, Cauwenberge P Van. 2002. Allergic rhinitis and its impact on asthma. ARIA. In  
533 collaboration with the World Health Organization. *Prim. Care Respir. J.* 11: 18–19.
- 534 Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. 2008. Allergic Rhinitis and  
535 its Impact on Asthma (ARIA) 2008\*. *Allergy* 63:8–160; doi:10.1111/j.1398-9995.2007.01620.x.
- 536 Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. 2013. Impact of allergic rhinitis symptoms  
537 on quality of life in primary care. *Int. Arch. Allergy Immunol.* 160:393–400;  
538 doi:10.1159/000342991.
- 539 Bouzigon E, Nadif R, Le Moual N, Dizier M-H, Aschard H, Boudier A, et al. 2015. Facteurs génétiques  
540 et environnementaux de l’asthme et de l’allergie : synthèse des résultats de l’étude EGEEA. *Rev.*  
541 *Mal. Respir.* 32:822–840; doi:10.1016/j.rmr.2014.12.005.
- 542 Burney PG, Luczynska C, Chinn S, Jarvis D. 1994. The European Community Respiratory Health  
543 Survey. *Eur. Respir. J.* 7:954–60; doi:10.1183/09031936.94.07050954.
- 544 Burte E, Leynaert B, Bono R, Brunekreef B, Bousquet J, Carsin A-E, et al. 2018. Association between  
545 air pollution and rhinitis incidence in two European cohorts. *Environ. Int.* 115:257–266;  
546 doi:10.1016/j.envint.2018.03.021.

- 547 D'Amato G, Pawankar R, Vitale C, Lanza M, Molino A, Stanziola A, et al. 2016. Climate Change and  
548 Air Pollution: Effects on Respiratory Allergy. *Allergy. Asthma Immunol. Res.* 8:391;  
549 doi:10.4168/aaair.2016.8.5.391.
- 550 D'Amato M, Cecchi C, Annesi-Maesano I, D'Amato G. 2018. News on Climate change, air pollution  
551 and allergic trigger factors of asthma. *J. Investig. Allergol. Clin. Immunol.* 28;  
552 doi:10.18176/jiaci.0228.
- 553 de Hoogh K, Gulliver J, Donkelaar A van, Martin R V., Marshall JD, Bechle MJ, et al. 2016.  
554 Development of West-European PM2.5 and NO2 land use regression models incorporating  
555 satellite-derived and chemical transport modelling data. *Environ. Res.* 151:1–10;  
556 doi:10.1016/j.envres.2016.07.005.
- 557 Diaz-Sanchez D. 2000. Pollution and the immune response: Atopic diseases - Are we too dirty or too  
558 clean? *Immunology* 101:11–18; doi:10.1046/j.1365-2567.2000.00108.x.
- 559 Eeftens M, Beelen R, De Hoogh K, Bellander T, Cesaroni G, Cirach M, et al. 2012. Development of  
560 land use regression models for PM2.5, PM 2.5 absorbance, PM10 and PMcoarse in 20 European  
561 study areas; Results of the ESCAPE project. *Environ. Sci. Technol.* 46:11195–11205;  
562 doi:10.1021/es301948k.
- 563 European Community Respiratory Health Survey II Steering Committee. 2002. The European  
564 Community Respiratory Health Survey II. *Eur. Respir. J.* 20:1071–9;  
565 doi:10.1183/09031936.02.00046802.
- 566 Guarnieri M, Balmes JR. 2014. Outdoor air pollution and asthma. *Lancet* 383:1581–92;  
567 doi:10.1016/S0140-6736(14)60617-6.
- 568 Hajat S, Haines A, Atkinson RW, Bremner SA, Anderson HR, Emberlin J. 2001. Association between  
569 air pollution and daily consultations with general practitioners for allergic rhinitis in London,  
570 United Kingdom. *Am. J. Epidemiol.* 153: 704–14.
- 571 Heinrich J. 2018. Air pollutants and primary allergy prevention. *Allergo J. Int.* 28:5–15;  
572 doi:10.1007/s40629-018-0078-7.
- 573 Huang KL, Liu SY, Chou CCK, Lee YH, Cheng TJ. 2017. The effect of size-segregated ambient  
574 particulate matter on Th1/Th2-like immune responses in mice. *PLoS One* 12:1–16;  
575 doi:10.1371/journal.pone.0173158.
- 576 Jacquemin B, Siroux V, Sanchez M, Carsin A-E, Schikowski T, Adam M, et al. 2015. Ambient Air  
577 Pollution and Adult Asthma Incidence in Six European Cohorts (ESCAPE). *Environ. Health*  
578 *Perspect.* 123:613–621; doi:10.1289/ehp.1408206.
- 579 Jang A-S, Jun YJ, Park MK. 2016. Effects of air pollutants on upper airway disease. *Curr. Opin. Allergy*

580 Clin. Immunol. 16:13–7; doi:10.1097/ACI.0000000000000235.

581 Katelaris CH, Lee BW, Potter PC, Maspero JF, Cingi C, Lopatin a, et al. 2012. Prevalence and diversity  
582 of allergic rhinitis in regions of the world beyond Europe and North America. *Clin. Exp. Allergy*  
583 42:186–207; doi:10.1111/j.1365-2222.2011.03891.x.

584 Kauffmann F. 1999. EGEA - descriptive characteristics. *Clin. Exp. Allergy* 29: 17–21.

585 Kauffmann F, Dizier MH, Pin I, Paty E, Gormand F, Vervloet D, et al. 1997. Epidemiological study of  
586 the genetics and environment of asthma, bronchial hyperresponsiveness, and atopy: phenotype  
587 issues. *Am. J. Respir. Crit. Care Med.* 156:S123-9; doi:10.1164/ajrccm.156.4.12tac9.

588 Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. 2000. Quality of life in allergic rhinitis and  
589 asthma. A population-based study of young adults. *Am J Respir Crit Care Med* 162:1391–1396;  
590 doi:10.1164/ajrccm.162.4.9912033.

591 Mady LJ, Schwarzbach HL, Moore JA, Boudreau RM, Kaffenberger TM, Willson TJ, et al. 2018. The  
592 association of air pollutants and allergic and nonallergic rhinitis in chronic rhinosinusitis. *Int.*  
593 *Forum Allergy Rhinol.* 8:369–376; doi:10.1002/alr.22060.

594 Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, et al. 2015.  
595 Phenotypes and endotypes of rhinitis and their impact on management: A PRACTALL report.  
596 *Allergy Eur. J. Allergy Clin. Immunol.* 70; doi:10.1111/all.12573.

597 Quillen DM, Feller DB. 2006. Diagnosing rhinitis: allergic vs. nonallergic. *Am. Fam. Physician* 73:  
598 1583–90.

599 Rage E, Siroux V, Künzli N, Pin I, Kauffmann F. 2009. Air pollution and asthma severity in adults.  
600 *Occup. Environ. Med.* 66:182–188; doi:10.1136/oem.2007.038349.

601 Rouve S, Didier A, Demoly P, Jankowski R, Klossek JM, Annesi-Maesano I. 2010. Numeric score and  
602 visual analog scale in assessing seasonal allergic rhinitis severity. *Rhinology* 48:285–291;  
603 doi:10.4193/Rhino09.208.

604 Shaaban R, Zureik M, Soussan D, Neukirch C, Heinrich J, Sunyer J, et al. 2008. Rhinitis and onset of  
605 asthma: a longitudinal population-based study. *Lancet* 372:1049–57; doi:10.1016/S0140-  
606 6736(08)61446-4.

607 Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, et al. 2011. Identifying adult  
608 asthma phenotypes using a clustering approach. *Eur. Respir. J.* 38:310–7;  
609 doi:10.1183/09031936.00120810.

610 Siroux V, Boudier A, Bousquet J, Bresson J-L, Cracowski J-L, Ferran J, et al. 2009. Phenotypic  
611 determinants of uncontrolled asthma. *J. Allergy Clin. Immunol.* 124:681–7.e3;

612 doi:10.1016/j.jaci.2009.06.010.

613 Wang J, Engvall K, Smedje G, Norbäck D. 2014. Rhinitis, asthma and respiratory infections among  
614 adults in relation to the home environment in multi-family buildings in Sweden. PLoS One 9:24–  
615 26; doi:10.1371/journal.pone.0105125.

616 Wu J-Z, Ge D-D, Zhou L-F, Hou L-Y, Zhou Y, Li Q-Y. 2018. Effects of particulate matter on allergic  
617 respiratory diseases. *Chronic Dis. Transl. Med.* 4:95–102; doi:10.1016/j.cdtm.2018.04.001.

618 Zhang F, Wang W, Lv J, Krafft T, Xu J. 2011. Time-series studies on air pollution and daily outpatient  
619 visits for allergic rhinitis in Beijing, China. *Sci. Total Environ.* 409:2486–92;  
620 doi:10.1016/j.scitotenv.2011.04.007.

621

622

Table 1 Characteristics of the participants, overall and by levels of score of severity

Variable	ALL N=1408	low severity N= 418	mild severity N=417	moderate severity N=251	high severity N=322	p-value
Score of severity, median [q1-q3]	4[2-6]	2[1-2]	4[3-4]	6[5-6]	8[7-9]	
Age, mean±sd	52.3±10.3	54.2±9.53	52.8±10.3	50.5±10.8	50.5±10.6	<0.001
Study, % EGEA	19.0	12.0	18.5	23.1	25.5	<0.001
Sex=women, %	54.4	51.2	51.8	60.2	57.5	0.059
Smoking status, %						
current	18.3	19.9	17.3	23.8	13.0	0.004
ex-smoker	38.3	40.3	41.5	30.7	37.8	
never	43.4	39.8	41.2	45.6	49.2	
Educational level, %						0.386
low	21.4	21.8	17.8	22.2	25.2	
medium	29.7	29.8	31.2	27.8	29.0	
high	48.9	48.4	51.0	50.0	45.9	
Asthma ever, %	28.2	18.0	28.4	30.9	38.9	<0.001
Asthma age of onset, mean±sd	16.9±13.9	17.1±13.9	18.5±14.7	16.2±13.8	13.8±14.7	0.43
Report of allergic rhinitis or hay fever ever, %	58.8	34.6	58.7	69.9	81.6	<0.001
Allergic sensitization, %	47.2	35.4	46.2	46.7	64.3	<0.001
Frequency of the symptoms=persistent, %	29.4	21.9	26	30	43.3	<0.001
Medication for rhinitis in the last 12 months=yes, %	42.0	16.7	37.0	52.7	68.8	<0.001
NO <sub>2</sub> , µg.m <sup>-3</sup> , mean±sd	29.9±14.6	28.2±14.1	30.5±14.9	30.5±15.1	30.8±14.2	0.047
PM <sub>10</sub> , µg.m <sup>-3</sup> , mean±sd	25.2±6.95	24.1±6.34	24.8±7.09	26.1±7.09	26.7±7.21	0.0009
PM <sub>2.5</sub> , µg.m <sup>-3</sup> , mean±sd	15.3±3.79	14.6±3.37	15.3±4.10	15.7±3.74	15.9±3.81	0.0018
Pmcoarse, µg.m <sup>-3</sup> , mean±sd	10.1±3.91	9.77±3.80	9.85±3.67	10.4±3.95	10.8±4.27	0.0231
Traffic load, mean	1600627	1460000	1510000	1790000	1750000	0.52
Traffic intensity, mean	5624	4328	5496	7227	6439	0.0109
Severity of runny nose						<0.001
no	26.6	57.7	23.0	11.6	2.80	
mild	37.1	37.8	59.5	35.1	37.1	
moderate/severe	36.2	4.60	17.5	53.4	88.2	
Severity of blocked nose						<0.001
no	32.5	72.7	26.6	14.3	2.20	
mild	25.3	21.8	44.4	20.3	9.00	
moderate/severe	42.2	5.50	29.0	65.3	88.8	
Severity of itchy nose						<0.001
no	44.7	82.5	46.8	27.9	6.20	



	mild	31.6	16.5	49.2	45.0	17.7	
	moderate/severe	23.7	1.00	4.10	27.1	76.1	
Severity of sneezing							<0.001
	no	30.4	60.8	28.8	16.7	3.70	
	mild	37.8	36.4	57.1	38.7	14.0	
	moderate/severe	31.8	2.87	14.2	44.6	82.3	
q1= quartile 1, q3= quartile 3, sd= standard deviation, p-value of the overall difference between the 4 categories of severity of rhinitis, p-value overall							

624

Figure 1: Flow-chart of the participants




Figure 2: Associations between air pollutant metrics and severity of rhinitis






Figure 3: Associations between air pollutant metrics and levels of severity score of rhinitis, among participants without allergic sensitization (A) and among participants with allergic sensitization (B)

A



B



## Figure legends

### **Figure 2: Associations between air pollutant metrics and severity of rhinitis**

Reference : low severity, Odds Ratio adjusted for age, sex, smoking status, asthma, allergic sensitization (and NO<sub>2</sub> background for traffic load and traffic Intensity), with city as a random intercept. Estimates are presented for an increase of 10 µg/m<sup>3</sup> for NO<sub>2</sub> and PM<sub>10</sub> and 5 µg/m<sup>3</sup> for PM<sub>2.5</sub> and PM<sub>coarse</sub>, and of 4,000,000 vehicles\*m/day for traffic load on all major roads in a 100m buffer and 5,000 vehicles/day for traffic density on the nearest road. Number reported below the pollutants correspond to the number of patients included in the adjusted analysis.

### **Figure 3: Associations between air pollutant metrics and levels of severity score of rhinitis, among participants without allergic sensitization (A) and among participants with allergic sensitization (B)**

Reference: low severity, Odds Ratio adjusted for age, sex, smoking status, asthma (and NO<sub>2</sub> background for traffic load and traffic Intensity), with city as a random intercept. Estimates are presented for an increase of 10 µg/m<sup>3</sup> for NO<sub>2</sub> and PM<sub>10</sub> and 5 µg/m<sup>3</sup> for PM<sub>2.5</sub> and PM<sub>coarse</sub>, and of 4,000,000 vehicles\*m/day for traffic load on all major roads in a 100m buffer and 5,000 vehicles/day for traffic density on the nearest road. Number reported below the pollutants corresponds to the number of patients included in the adjusted analysis